Tag Archive for: drug resistance

Phase 1 Trial Investigates MAO-A Inhibition With ITR-251 to Overcome Prostate Cancer Resistance

A new Phase 1 clinical trial  will investigate ITR-251, an experimental inhibitor of monoamine oxidase A (MAO-A), as a potential treatment for advanced solid tumours and metastatic castration-resistant prostate cancer (mCRPC). What makes this investigation unusual is its molecular target. MAO-A is an enzyme best known for breaking down neurotransmitters and other monoamines. However, research […]

Weizmann Institute Identifies Immunotherapy Targets in Drug-Resistant Prostate Cancer

Researchers from Israel’s Weizmann Institute of Science have unveiled a promising immunotherapy strategy that targets drug-resistant cancers by exploiting the very genetic mutations responsible for treatment failure. ​ The approach centers on a computational tool called SpotNeoMet, which scans large patient datasets to identify recurrent resistance mutations that generate neo-antigens, unique protein fragments displayed exclusively […]

DiWB-1: A Targeted Approach to Prostate Cancer Treatment

DiWB-1, a luteinizing hormone-releasing hormone (LHRH)-targeted peptide-drug conjugate (PDC) with PI3K inhibition properties, is an emerging candidate that may offer a new way to treat prostate cancer. Its design and mechanism suggest potential for addressing some of the limitations of current treatments, particularly for resistant cases. DiWB-1 is described as an LHRH-targeted PDC, a class […]